The global coronavirus immunoassay market continues to witness steady growth, reaching USD 3.7 billion in 2021 and is projected to exceed USD 6.9 billion by 2032, expanding at a CAGR of 5.5% during the forecast period.
The market’s growth is fueled by rising demand for rapid and accurate diagnostic solutions, driven by the ongoing emergence of COVID-19 variants and increased investment in infectious disease research. Immunoassay kits and reagents remain the dominant segment, accounting for approximately 64.0% of the market share in 2021, owing to their affordability, efficiency, and widespread use in diagnostic settings.
Discover Market Shifts: Secure Your Sample Report Now! https://www.futuremarketinsights.com/report-sample#5245502d47422d3135313131
Furthermore, technological advancements in the field, including point-of-care testing, automation in immunoassay platforms, and AI-driven diagnostic tools, are reshaping the market landscape. With governments and healthcare organizations prioritizing early detection and preparedness for future outbreaks, demand for highly sensitive and reliable immunoassays is expected to remain robust.
As the market advances, key industry players are focusing on enhancing test accuracy, reducing turnaround times, and expanding diagnostic accessibility to meet the evolving healthcare needs worldwide.
Key Market Drivers:
- Increasing Disease Prevalence: The surge in both chronic and infectious diseases necessitates reliable diagnostic tools, positioning immunoassays as essential in modern healthcare.
- Technological Advancements: Innovations such as chemiluminescent immunoassays (CLIA) and multiplex flow immunoassays (MFI) have enhanced the sensitivity and specificity of immunoassays, broadening their clinical applications.
- Biopharmaceutical Growth: The expanding biotechnology and biopharmaceutical sectors utilize immunoassays extensively, from product development to quality control, further propelling market growth.
Market Segmentation and Opportunities:
- Product Segments: Immunoassay kits and reagents dominate the market, accounting for 61% of revenue in 2022, with software and services projected to grow at a CAGR of 5.68%.
- Technological Segments: Enzyme-Linked Immunosorbent Assay (ELISA) remains the leading technology, attributed to its widespread use in diagnosing chronic conditions and infectious diseases.
- Geographical Insights: North America leads the market, with the U.S. accounting for approximately 95.7% of the North American immunoassay market in 2021.
The Asia Pacific region is anticipated to experience the fastest growth rate from 2023 to 2032, driven by improving healthcare infrastructure and increasing healthcare investments.
“Increasing demand for reliable diagnostic tests and equipment, along with rising investments in the expansion of the healthcare infrastructure across emerging economies will augment the growth in the market,” says an FMI analyst.
Heightened Market Interest: Our Complete Report Delivers Extensive Analysis and Trends! https://www.futuremarketinsights.com/reports/coronavirus-immunoassay-market
Strategic Implications for Decision Makers:
For industry leaders and stakeholders, the following strategic considerations are paramount:
- Investment in Innovation: Allocating resources to research and development can lead to the creation of advanced immunoassay technologies, meeting the evolving demands of healthcare diagnostics.
- Market Expansion: Focusing on emerging economies with growing healthcare needs presents opportunities for market penetration and revenue growth.
- Regulatory Navigation: Understanding and adapting to stringent regulatory requirements is crucial for the successful approval and commercialization of immunoassay products.
- Collaborative Ventures: Engaging in partnerships and acquisitions can enhance product portfolios and expand market reach, as evidenced by recent strategic collaborations in the industry.
In conclusion, the immunoassay market is on an upward trajectory, offering substantial opportunities for growth and innovation. Decision makers equipped with strategic insights and a commitment to advancing diagnostic technologies are well-positioned to capitalize on this expanding market.
Key Takeaways:
- Based on product type, sales in the immunoassay kits & reagents segment are forecast to increase at a 5.4% CAGR through 2032.
- In terms of assay type, the LFA assays segment will hold 45% of the total market share by 2032.
- By purpose, demand in the clinical use segment will increase at a 5.1% CAGR through 2032.
- Based on specimen type, Nasopharynx specimens are leading the market.
- Clinical diagnostics hold around 4% of the coronavirus immunoassay market, owing to the high volumes of the infected patient population, post the advent of the COVID-19 pandemic.
- Demand in the healthcare sector will grow at a 4.9% CAGR over the assessment period.
Competition Landscape:
- Surmodics, Inc.
- MESO SCALE DIAGNOSTICS, LLC.
- Abbott (Core Laboratory)
- Siemens-healthineers (Siemens Medical Solutions USA, Inc)
- PerkinElmer Inc.
- BD Biosciences
- ThermoFisher Scientific Inc.
- Zoetis Inc.
- Promega Corporation
- F. Hoffmann- La Roche Ltd.
- Other
This scenario promotes market competition, thus, key companies typically use high-impact marketing campaigns and launch test kits with variety of innovation to attract customers. For instance:
- In May 2022, Thermo Fisher Scientific and LabShares partnered to support the emerging Boston biotech ecosystem. This will help validate and commercialize the next generation of life-saving therapies, including the biotech and life science segments.
- In May 2022, Babson and BD expanded their strategic partnership to advance diagnostic blood collection that will allow to move blood sample collection into new care settings, including enabling patients to collect blood samples at home for diagnostic testing.
- In December 2021, PerkinElmer launched NEXTFLEX Variant-Seq SARS-CoV-2 Kit v2 to strengthen SARS-CoV-2 surveillance.
- In April 2022, Abbott had overall 12 COVID testing solutions like BinaxNOW COVID-19 Antigen Self-Test and Panbio COVID-19 Antigen Self-Test. It also took the initiative of the Pandemic Defense Coalition, the first-ever industry-led scientific and global health partnership dedicated to the early detection of and rapid response to future pandemic threats.
Understand the Future of Healthcare with Our Analysis! https://www.futuremarketinsights.com/industry-analysis/in-vitro-diagnostics-devices
Key Market Segments Covered in Coronavirus Immunoassay Industry Research:
By Product:
- Immunoassay Kits & Reagents
- Kits
- Primary Antibodies
- Secondary antibodies
- Immunoassay Substrates
- Immunoassay Buffers
- Analysers & Instrument
- Consumables
- Software
By Assay:
- ELISA
- FIA
- CLIA
- LFA
- Others
By Purpose:
- Research Use Only
- Clinical Use
By Specimen:
- Blood
- Saliva
- Nasopharynx
- Cell Culture Samples
By Application:
- Clinical Diagnostics
- Drug Discovery
- Screening of diseases & disorders
By End User:
- Healthcare Industry
- Human Use
- Veterinary
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
